Reduced faecal excretion of F4+-E coli by the intramuscular immunisation of suckling piglets by the addition of 1alpha,25-dihydroxyvitamin D3 or CpG-oligodeoxynucleotides.
In this study it was analysed whether intramuscular (IM) immunisation of piglets with F4 during the suckling period could protect against oral challenge with F4(+)-Escherichia coli and whether addition of 1alpha,25(OH)(2)D(3) or CpG-ODN could improve this protection.F4-seronegative F4-receptor positive pigs were divided into four groups of five pigs each. The pigs were intramuscularly injected with F4 fimbriae only or supplemented with 1alpha,25(OH)(2)D(3) (D(3)-group) or CpG-ODN (CpG-group). The control group received PBS in IFA. Seven days after the second immunisation, all pigs were intragastrically inoculated with 1 x 10(10) CFU of F4(+)-E. coli. All F4-injected groups, showed a reduced faecal excretion of F4(+)-E. coli. However, this reduction was only statistically significant in the D(3)-group 2 days post challenge. Pigs in the latter group showed a secondary antibody response upon challenge, indicating that F4-primed memory B-cells were present in the gut-associated lymphoid tissues at that moment.CpG-ODN, on the other hand, did not enhance the F4-specific antibody response. However, CpG-ODN significantly increased the F4-specific as well as mitogen-induced proliferation of peripheral blood monomorphonuclear cells indicating a direct or indirect overall effect on T-lymphocytes. In conclusion, supplementation with 1alpha,25(OH)(2)D(3) or CpG-ODN improved protection against an F4(+)-E. coli infection. This protection was most obvious for 1alpha,25(OH)(2)D(3) and indicates its potential use in veterinary vaccines against enteropathogens.
Van der Stede
Y
Y
Laboratory of Veterinary Immunology, Faculty of Veterinary Medicine, Universiteit Gent Salisburylaan 133, B-9820, Merelbeke, Belgium. yves.vanderstede@rug.ac.be
Cox
E
E
Verdonck
F
F
Vancaeneghem
S
S
Goddeeris
B M
BM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000833:Animals, Suckling; D000907:Antibodies, Bacterial / Q000097:blood; D002117:Calcitriol / Q000008:administration & dosage*; D004926:Escherichia coli / Q000276:immunology / Q000302:isolation & purification* / Q000472:pathogenicity; D004927:Escherichia coli Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D022361:Escherichia coli Vaccines / Q000008:administration & dosage*; D005243:Feces / Q000382:microbiology; D010861:Fimbriae, Bacterial / Q000276:immunology; D018928:Immunity, Mucosal; D007273:Injections, Intramuscular; D008213:Lymphocyte Activation; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage*; D034421:Sus scrofa; D013553:Swine Diseases / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D015430:Weight Gain
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; C408982:CPG-oligonucleotide; D022361:Escherichia coli Vaccines; D009838:Oligodeoxyribonucleotides; D002117:Calcitriol